PUBLISHER: BCC Research | PRODUCT CODE: 1688869
PUBLISHER: BCC Research | PRODUCT CODE: 1688869
The global market for cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $116.1 billion in 2024 to reach $168.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2029.
The global market for lung cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $16.2 billion in 2024 to reach $29.0 billion by 2029, at a CAGR of 12.4% from 2024 to 2029.
The global market for breast cancer therapeutics emphasizing recurrent and metastatic divisions is expected to grow from $13.7 billion in 2024 to reach $23.6 billion by 2029, at a CAGR of 11.4% from 2024 to 2029.
Both qualitative and quantitative data on the current dynamics impacting the global cancer therapeutics market are presented in this report. It discusses the history of cancer, its different forms, its pathophysiology, its stages of development and its mechanisms of metastasis and recurrence. It also incorporates the disease burden by knowing the epidemiology of different cancers. Treatment patterns that include both non-pharmacological (e.g., radiation, surgery) and pharmacological (e.g., hormonal therapy, targeted therapy, cytotoxic/chemotherapy, combinatorial therapy) approaches are discussed to illustrate the various therapeutic options available to patients.
Analyses of the most popular products, the state of clinical trials and new product approvals are also included in the report. The demographics of the major regions-North America, Europe, Asia-Pacific and the Rest of the World-as well as their prospects for growth, are summarized. The profiles of leading companies and the strategies of international businesses involved in the cancer treatment sector are also discussed.
Estimations of the market size for therapies that treat cancer metastases and recurrence states are included in the scope. Cancer types noted in this report include:
Additional growth potential and forecast data are discussed for the cancer therapeutics market, as well as for the cancer types, regions and countries.
For market estimates, data are provided for 2023 as the base year, with forecasts for the period of 2024 through 2029.